Kamran Hosseini | Biochemistry | Best Researcher Award

Published on by Academic Achievements

Best Researcher Award

Kamran Hosseini
Affiliation Shiraz University of Medical Sciences
Country Iran
Scopus ID 57226155096
Documents 32
Citations 638
h-index 10
Subject Area Biochemistry, Genetics and Molecular Biology
Event International Academic Achievements & Awards
ORCID 0000-0003-1189-7143

Kamran Hosseini
Shiraz University of Medical Sciences, Iran

The Best Researcher Award recognizes distinguished scholars whose sustained scientific achievements, publication record, research quality, and academic influence demonstrate excellence within their respective disciplines. Kamran Hosseini has established an active research profile in biochemistry, genetics, molecular biology, neuroscience, and clinical medicine through peer-reviewed publications addressing neurological disorders, molecular signaling pathways, spinal surgery, and translational biomedical research.[1] His scholarly output, citation impact, and international visibility provide evidence of continued contributions to medical science and interdisciplinary biomedical research.[2]

Abstract

Kamran Hosseini has contributed to contemporary biomedical research through investigations spanning molecular biology, neurology, neurosurgery, gene therapy, spinal disorders, and translational medicine. His publication portfolio demonstrates interdisciplinary collaboration while integrating laboratory discoveries with clinical applications. Current research includes viral vector-mediated therapeutic strategies, spinal surgery outcomes, neurological disease mechanisms, and complex neurosurgical case management.[3] Such work reflects sustained engagement with evidence-based medicine and translational biomedical science.

Keywords

Best Researcher Award, Kamran Hosseini, Neuroscience, Molecular Biology, Gene Therapy, AAV Vectors, Biochemistry, Genetics, Neurosurgery, Clinical Research, Biomedical Science, Translational Medicine, Shiraz University of Medical Sciences.

Introduction

Recognition through a Best Researcher Award is commonly based upon sustained scholarly productivity, measurable research impact, publication quality, interdisciplinary collaboration, and contributions to scientific advancement. Researchers working across molecular biology and clinical medicine play an important role in translating laboratory discoveries into practical healthcare improvements.[1] Kamran Hosseini’s research activities illustrate this translational approach by integrating basic biological science with clinical neurosurgical investigations.

Research Profile

  • Affiliation: Shiraz University of Medical Sciences
  • Primary discipline: Biochemistry, Genetics and Molecular Biology
  • Scopus documents: 32
  • Total citations: 638
  • Scopus h-index: 10
  • Research interests include neuroscience, molecular signaling pathways, neurosurgery, spinal disorders, translational medicine, and gene therapy.

Research Contributions

The research portfolio demonstrates contributions across molecular neuroscience, neurological disorders, spinal surgery, and clinical case studies. Recent investigations evaluate adeno-associated virus (AAV) vectors for therapeutic modulation of cellular signaling pathways, assess perioperative interventions to reduce blood loss during spinal fusion procedures, and document rare neurosurgical cases that contribute to evidence-based clinical decision making.[3] These publications illustrate interdisciplinary collaboration between molecular biology and clinical neuroscience while supporting translational healthcare research.

Publications

  • AAV Vector‐Mediated Modulation of Signaling Pathways in Neurological Disorders, Cell Biochemistry and Function (2026). DOI: 10.1002/cbf.70270.
  • Prophylactic effects of tranexamic acid in spinal fusion, Egyptian Journal of Neurosurgery (2026). DOI: 10.1186/s41984-026-00560-8.
  • Giant Lumbosacral Meningioma Without Dural Attachment in an Adolescent, International Medical Case Reports Journal (2026). DOI: 10.2147/IMCRJ.S578462.
  • Management of Intrathoracic Huge Meningocele in Neurofibromatosis Type-1, International Medical Case Reports Journal (2026). DOI: 10.2147/IMCRJ.S578419.
  • Kümmell’s Disease in Benign Vertebral Compression Fractures, Clinical Neurology and Neurosurgery (2026). DOI: 10.1016/j.clineuro.2025.109262.

Research Impact

Available bibliometric indicators demonstrate an established publication record comprising 32 indexed documents, 638 citations, and an h-index of 10. These metrics indicate continued scholarly engagement and measurable scientific visibility within biomedical research.[1] The combination of molecular biology, neuroscience, and clinical investigations contributes to interdisciplinary knowledge relevant to both research laboratories and healthcare practice.

Award Suitability

Based on the available academic profile, publication activity, citation performance, interdisciplinary research scope, and contributions to peer-reviewed biomedical literature, Kamran Hosseini demonstrates characteristics commonly evaluated for academic recognition programs such as the Best Researcher Award. His research integrates molecular science with clinical application while contributing to neurological disease research, spinal surgery, and translational medicine through internationally published scientific work.[2]

Conclusion

Kamran Hosseini’s scholarly record reflects sustained participation in biomedical research characterized by interdisciplinary collaboration, clinically relevant investigations, and measurable academic impact. His publication portfolio, citation metrics, and recent contributions to neuroscience and molecular biology illustrate a research trajectory aligned with internationally recognized standards of scientific excellence and make his profile appropriate for consideration within academic recognition initiatives.

References

  1. Elsevier. (n.d.). Scopus author details: Kamran Hosseini, Author ID 57226155096. Scopus.
    https://www.scopus.com/pages/authors/57226155096
  2. ORCID. (n.d.). Kamran Hosseini ORCID Record.
    https://orcid.org/0000-0003-1189-7143
  3. Hosseini K. et al. (2026). AAV Vector‐Mediated Modulation of Signaling Pathways in Neurological Disorders: Insights From Cellular, Animal, and Human Studies. Cell Biochemistry and Function. DOI: https://doi.org/10.1002/cbf.70270
  4. Hosseini K. et al. (2026). Prophylactic effects of tranexamic acid in spinal fusion. Egyptian Journal of Neurosurgery. https://doi.org/10.1186/s41984-026-00560-8
  5. Recent peer-reviewed publications in International Medical Case Reports Journal and Clinical Neurology and Neurosurgery (2026). https://doi.org/10.2147/IMCRJ.S578462

Promise Paul | Biochemistry | Innovative Research Award

Published on by Academic Achievements

Innovative Research Award

Promise Paul
Affiliation Michael Okpara University of Agriculture, Umudike
Country Nigeria
Google Scholar ID o4j7GMIAAAAJ
Documents 6
Citations 24
h-index 1
Subject Area Biochemistry
Event International Academic Achievements & Awards
ORCID 0009-0002-7532-8409

Researcher: Promise Paul
Institution: Michael Okpara University of Agriculture, Umudike

Promise Paul is a researcher affiliated with Michael Okpara University of Agriculture, Umudike, Nigeria, whose scholarly activities are centered on biochemistry, toxicology, environmental health, immunology, and emerging public health technologies. His published research demonstrates interdisciplinary collaboration involving biochemical mechanisms, environmental risk assessment, immunomodulation, and artificial intelligence applications in healthcare. Based on the available scholarly record, his work reflects an emphasis on translating laboratory findings into practical biomedical and public health applications.[1][2]

Abstract

Promise Paul has contributed to a growing body of interdisciplinary research spanning biochemical sciences, environmental toxicology, occupational exposure assessment, immunology, and public health. His publications investigate volatile organic compound interactions with biological receptors, bioaccumulation of toxic elements in aquatic organisms, antioxidant mechanisms, immune regulation, and artificial intelligence applications in disease surveillance. Collectively, these studies contribute to understanding disease prevention, environmental safety, and biomedical innovation while supporting evidence-based public health practices.[2][3]

Keywords

Biochemistry, Environmental Toxicology, Occupational Health, Drug Design, Artificial Intelligence, Public Health, Immunology, Oxidative Stress

Introduction

Modern biomedical research increasingly depends on interdisciplinary collaboration to address complex health and environmental challenges. Promise Paul’s research portfolio reflects this approach by integrating biochemical investigation with environmental science, clinical perspectives, and computational technologies. His collaborative publications examine toxicological mechanisms, disease prevention, environmental monitoring, and innovative analytical strategies that support scientific understanding across multiple disciplines.[2]

Research Profile

The available publication record indicates research interests spanning molecular toxicology, pharmacology, environmental biochemistry, immunomodulation, veterinary science, and digital public health. His collaborative studies frequently investigate biological responses to toxic compounds, mechanisms of oxidative stress, environmental contaminants, and innovative approaches for disease surveillance using artificial intelligence technologies. These areas collectively contribute to improving scientific understanding of health risks and preventive strategies.[1]

Research Contributions

  • Investigated volatile organic compound interactions with drug receptors to support rational drug discovery strategies.
  • Contributed to environmental health studies evaluating toxic element bioaccumulation in commercially important fish species.
  • Participated in immunology research examining therapeutic approaches for congenital immunodeficiencies.
  • Co-authored research exploring ethical implementation of artificial intelligence for public health surveillance.
  • Investigated antioxidant effects of L-Arginine against carbon tetrachloride-induced oxidative damage in experimental animal models.

Publications

  1. Volatile organic compound–drug receptor interactions: a potential tool for drug design in the search for remedies for increasing toxic occupational exposure. Processes, 13(1), 154. DOI: https://doi.org/10.3390/pr13010154
  2. Bioaccumulation and Human Health Risk Assessment of Potentially Toxic Elements in Commercial Fish Species. International Journal of Environmental Research and Public Health, 23(7), 827.
  3. Immunomodulation in Congenital Immunodeficiencies: Targeting Innate and Adaptive Pathways. Clinical Medicine and Integrative Therapies, 1(1), 36–52.
  4. Artificial Intelligence for Public Health Surveillance: Promises, Pitfalls, and an Ethics-Equity Roadmap for Deployment. Disease Prevention and Epidemiology, 1(1), 22–39.
  5. Antioxidant Effects of L-Arginine on Redox Profile of Carbon Tetrachloride (CCl4)-Intoxicated Albino Rats. Journal of Sustainable Veterinary & Allied Sciences, 7(4), 385–391.

Research Impact

Although currently representing an early-stage publication profile, the available scholarly metrics indicate growing visibility through peer-reviewed publications and citations. The interdisciplinary nature of these investigations contributes to knowledge spanning environmental safety, biomedical science, toxicology, and digital health while encouraging collaboration across multiple scientific disciplines.[2]

Award Suitability

Promise Paul’s research portfolio demonstrates characteristics commonly considered for emerging research recognition, including interdisciplinary collaboration, publication in peer-reviewed journals, investigation of contemporary biomedical and environmental issues, and contributions to public health research. The Innovative Research Award appropriately recognizes researchers developing multidisciplinary scientific approaches with potential societal relevance.[1][2]

Conclusion

Promise Paul has established an emerging interdisciplinary research profile focused on biochemistry, environmental health, immunology, toxicology, and artificial intelligence applications in medicine. His collaborative publications demonstrate scientific engagement with important biomedical and environmental challenges, supporting continued academic development and making his work consistent with the objectives of recognizing innovative scientific research.

References

  1. Google Scholar. (n.d.). Promise Paul – Google Scholar Citations Profile.
    https://scholar.google.com/citations?user=o4j7GMIAAAAJ&hl=en&oi=ao
  2. Processes. (2025). Volatile organic compound–drug receptor interactions: a potential tool for drug design in the search for remedies for increasing toxic occupational exposure.DOI:https://doi.org/10.3390/pr13010154
  3. ORCID. (n.d.). Promise Paul ORCID Record.
    https://orcid.org/0009-0002-7532-8409
  4. Crossref DOI Foundation. (n.d.). DOI Metadata and Scholarly Record Services.

Narendra Verma | Biochemistry | Research Excellence Award

Published on by Academic Achievements

Research Excellence Award

Narendra Verma
Affiliation Centre of BioMedical Research Lucknow
Country India
Scopus ID 57191708464
Documents 18
Citations 1,303
h-index 10
Subject Area Biochemistry, Genetics and Molecular Biology
Event International Academic Achievements & Awards

Narendra Verma
Centre of BioMedical Research Lucknow, India

Narendra Verma is an Indian molecular biologist and geneticist currently serving as Assistant Professor in the Department of Systems Biology at the Centre of Biomedical Research (CBMR), Lucknow. His research spans genetics, transcriptomics, metabolic biology, cancer signaling, adipose tissue physiology, and cellular regulatory mechanisms. Through collaborations with leading international laboratories, he has contributed to advances in cancer biology, obesity research, metabolic disorders, and molecular signaling pathways.[1]

Abstract

Narendra Verma has established a multidisciplinary research portfolio focused on molecular genetics, cancer biology, obesity, metabolic disorders, and transcriptomic regulation. His scholarly contributions include highly cited publications in leading journals such as Nature, Cancer Cell, Oncogene, Stem Cells, and Journal of Biological Chemistry. His current work investigates glycophagy-mediated metabolic regulation in diabetes-induced fatty liver disease through an ICMR-funded project.[2]

Keywords

Genetics, Molecular Biology, Transcriptomics, Cell Signaling, Cancer Biology, Obesity, Metabolism, Adipose Tissue, Diabetes, Glycophagy.

Introduction

Following academic training in biotechnology and molecular genetics in India and Italy, Dr. Verma developed expertise in transcriptional regulation, metabolic signaling, and disease mechanisms. His research integrates experimental biology with translational applications aimed at understanding metabolic and oncogenic processes.[3]

Research Profile

His investigations have explored Sox2-mediated tumorigenesis, YAP signaling regulation, adipocyte metabolism, thermogenesis, inflammatory signaling, and metabolic dysfunction. These studies combine cellular, molecular, and genomic approaches to address fundamental biomedical questions.[4]

Research Contributions

  • Identified Sox2-dependent mechanisms in osteosarcoma development.
  • Advanced understanding of YAP signaling in cancer progression.
  • Contributed to landmark Nature research on fungal microbiome-driven pancreatic oncogenesis.
  • Investigated thermogenic and adipocyte regulatory pathways.
  • Leading ICMR-funded studies on glycophagy and fatty liver disease.

Publications

Notable publications include articles in Nature, Cancer Cell, Oncogene, Stem Cells, Aging Cell, ATVB, and Journal of Biological Chemistry. Several publications have appeared in journals with significant impact factors and international visibility.[5]

Research Impact

According to Scopus data, Dr. Verma has accumulated over 1,300 citations across 18 indexed publications with an h-index of 10. His work has influenced research in cancer biology, metabolism, immunology, and molecular medicine, reflecting broad interdisciplinary relevance.[1]

Award Suitability

Dr. Verma demonstrates strong eligibility for research excellence recognition due to his impactful publication record, international collaborations, competitive grant funding, and sustained contributions to molecular and biomedical sciences. His ongoing ICMR-supported research further highlights his active role in advancing translational health research.

Conclusion

The academic achievements of Dr. Narendra Kumar Verma illustrate a productive career focused on understanding the molecular basis of disease. Through influential publications, collaborative science, and funded research programs, he continues to contribute to biomedical innovation and scientific advancement.

References

  1. Elsevier. (2026). Scopus Author Details: Narendra Kumar Verma, Author ID 57191708464.
    https://www.scopus.com/authid/detail.uri?authorId=57191708464
  2. ICMR Project Record. Unraveling the Glycophagy Receptors: Targeting HSF1-STBD1 Axis to Manage Metabolic Homeostasis in Diabetes-Induced Fatty Liver. https://cbmr.res.in/faculty-profile-single.php?qwr=DTM-FCT20#gsc.tab=0
  3. Verma N. et al. Journal of Biological Chemistry. 2020.
  4. Maurizi G., Verma N., et al. Oncogene. 2018.
  5. Aykut B., Pushalkar S., Verma N., et al. Nature. 2019.
    https://doi.org/10.1038/s41586-019-1608-2

David Greening | Proteomics | Innovative Research Award

Published on by Academic Achievements

Prof. David Greening | Proteomics | Innovative Research Award

Lab Head at Baker Heart & Diabetes Institute, Australia

Professor David Greening is an internationally recognized biomedical scientist specializing in molecular proteomics and extracellular vesicle (EV) biology. He serves as Head of Molecular Proteomics at the Baker Heart & Diabetes Institute and holds the prestigious Helen Amelia Hains Fellowship. He is also Director of the Proteomics & Metabolomics Platform at La Trobe University, with affiliate appointments at Monash University and the University of Melbourne. His research focuses on using advanced mass spectrometry and multi-omics technologies to understand complex intercellular communication, particularly in cardiovascular disease and cancer. With a Ph.D. from the University of Melbourne in collaboration with the Ludwig Institute for Cancer Research, and postdoctoral training at leading institutions including WEHI and the Institute for Systems Biology in the USA, Professor Greening has built a distinguished academic and translational research career. He has authored over 146 peer-reviewed publications, received numerous national and international awards, and actively collaborates with industry to advance EV-based diagnostics and therapeutics.

Academic Profile

SCOPUS

ORCID

GOOGLE SCHOLAR

Education

Professor David Greening completed his Bachelor of Science with Honours at the University of Melbourne, where he developed a strong foundation in biomedical science and molecular biology. He went on to earn his Ph.D. from the University of Melbourne in collaboration with the Ludwig Institute for Cancer Research, focusing on cancer biology, proteomics, and cellular signaling pathways. Following his doctoral studies, he undertook advanced postdoctoral training at several prestigious institutions, including the Walter and Eliza Hall Institute of Medical Research (WEHI), the Institute for Systems Biology in Seattle, USA, and La Trobe University in Melbourne. These experiences further deepened his expertise in high-throughput proteomics, biomarker discovery, systems biology, and translational medicine, laying the groundwork for his future leadership in molecular proteomics and extracellular vesicle research.

Experience

Professor David Greening has built an outstanding career as a biomedical scientist, currently serving as the Head of Molecular Proteomics at the Baker Heart & Diabetes Institute and holding the prestigious Helen Amelia Hains Fellowship. He is also the Director of the Proteomics & Metabolomics Platform at La Trobe University, with affiliate academic appointments at Monash University and the University of Melbourne. His professional experience spans leadership in advanced proteomics, systems biology, and extracellular vesicle (EV) research, particularly focusing on cardiovascular biology and cancer. Since joining the Baker Institute in 2019, Professor Greening has established a high-impact research program integrating mass spectrometry, nanobiotechnology, lipidomics, and bioinformatics to decode intercellular signaling and EV-mediated mechanisms in health and disease. He has led numerous industry collaborations with leading biotech and pharmaceutical companies including Takeda, Thermo Fisher, CSL, VivaZome, and Tithon Biotech. In addition to his research leadership, he has served as President of the Australian and New Zealand Society for Extracellular Vesicles and is Chair of the ISEV2024 conference. His translational efforts have contributed to the development of novel diagnostics and therapeutic strategies, advancing the clinical and commercial potential of EV-based technologies.

Research Interests

Professor David Greening’s research interests center on the dynamic field of extracellular vesicles (EVs), molecular proteomics, and systems biology, with a strong emphasis on cardiovascular biology, regenerative medicine, and cancer. He is particularly focused on understanding the complex roles of EVs in intercellular communication, their molecular architecture, and their potential as biomarkers and therapeutic vehicles. His work employs advanced mass spectrometry and multi-omics technologies—including proteomics, lipidomics, and metabolomics—to unravel the intricate signaling networks governing heart disease, tissue remodeling, and immune responses. Professor Greening is also deeply engaged in the development of EV-based diagnostic tools and acellular therapeutics, aiming to translate molecular insights into clinical applications. His interdisciplinary approach bridges basic science with translational outcomes, advancing the frontiers of precision medicine and next-generation healthcare solutions.

Awards

Professor David Greening has received numerous prestigious awards in recognition of his pioneering work in proteomics and extracellular vesicle (EV) research. In 2024, he was honored as a Lifetime Member of both the International Society for Extracellular Vesicles (ISEV) and the Australia and New Zealand Society for Extracellular Vesicles. That same year, he was presented with the ISEV Emerging Leader Award and was recognized among the Top 250 Researchers in all scientific fields in Australia by the Australian Research Magazine, which also acknowledged him as a national field leader in proteomics and protein chemistry from 2021 to 2025. His global impact was further recognized in 2023 when he was listed among Stanford University’s top 1% most-cited researchers and received Wiley’s Top 0.1% Citation Impact Award. These accolades underscore Professor Greening’s exceptional contributions to biomedical science, translational proteomics, and his leadership in advancing the clinical utility of extracellular vesicles.

Publications 📚 

Minimal information for studies of extracellular vesicles 2018 (MISEV2018): a position statement of the International Society for Extracellular Vesicles and update of the …

Cited: 10265

Minimal information for studies of extracellular vesicles (MISEV2023): From basic to advanced approaches

Cited: 1713

Extracellular vesicles in cancer—implications for future improvements in cancer care

Cited: 1446

Comparison of ultracentrifugation, density gradient separation, and immunoaffinity capture methods for isolating human colon cancer cell line LIM1863-derived exosomes.

Cited: 1398

Extracellular vesicle isolation and characterization: toward clinical application

Cited:  981

A protocol for isolation, purification, characterization, and functional dissection of exosomes

Cited: 848

Conclusion

Prof. David Greening’s transformative research, translational impact, and sustained international leadership epitomize the essence of the Innovative Research Award. His ability to bridge fundamental biology with clinical application and his success in commercializing scientific breakthroughs position him as a premier candidate for this distinguished recognition.